HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sublingual ketorolac and sublingual piroxicam are equally effective for postoperative pain, trismus, and swelling management in lower third molar removal.

AbstractOBJECTIVE:
Lower third molar removal provides a clinical model for studying analgesic drugs. The present study's aim was to compare the clinical efficacy of sublingual ketorolac and sublingual piroxicam in managing pain, trismus and swelling after lower third molar extraction in adult volunteers.
STUDY DESIGN:
In this double-blinded, randomized, crossover investigation, 47 volunteers received for 4 days ketorolac sublingually (10 mg 4 times daily) and piroxicam sublingually (20 mg once daily) during 2 separate appointments after lower third molar extraction of symmetrically positioned lower third molars. A surgeon evaluated objective parameters (surgery duration, mouth opening, rescue analgesic medication, and facial swelling) and volunteers documented subjective parameters (postoperative pain and global evaluation), comparing postoperative results for a total of 7 days after surgery. The means of the objective and subjective parameters were compared for statistical significance (P < .05).
RESULTS:
Volunteers reported low pain scores during the postoperative period when treated with either sublingual ketorolac or piroxicam. Also, volunteers ingested similar amounts of analgesic rescue medication (paracetamol) when they received either drug sublingually (P > .05). Additionally, values for mouth openings measured just before surgery and immediately after suture removal 7 days later were similar among volunteers (P > .05), and the type of nonsteroidal antiinflammatory drug (NSAID) used in this study showed no significant differences between swellings on the second or seventh days after surgery (P > .05).
CONCLUSIONS:
Pain, trismus, and swelling after lower third molar extraction, independent of surgical difficulty, were successfully controlled by sublingual ketorolac (10 mg 4 times daily) or sublingual piroxicam (20 mg once daily), and no significant differences were observed between the NSAIDs evaluated.
AuthorsPaulo A K Trindade, Fernando P M Giglio, Bella L Colombini-Ishikiriama, Adriana M Calvo, Karin Cristina S Modena, Debora A Ribeiro, Thiago J Dionísio, Daniel T Brozoski, José Roberto P Lauris, Flávio Augusto C Faria, Carlos F Santos
JournalOral surgery, oral medicine, oral pathology and oral radiology (Oral Surg Oral Med Oral Pathol Oral Radiol) Vol. 114 Issue 1 Pg. 27-34 (Jul 2012) ISSN: 2212-4411 [Electronic] United States
PMID22732846 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2012 Elsevier Inc. All rights reserved.
Chemical References
  • Cyclooxygenase Inhibitors
  • Piroxicam
  • Ketorolac
Topics
  • Analysis of Variance
  • Cross-Over Studies
  • Cyclooxygenase Inhibitors (administration & dosage)
  • Double-Blind Method
  • Edema (drug therapy, etiology)
  • Female
  • Humans
  • Ketorolac (administration & dosage)
  • Male
  • Mandible (surgery)
  • Molar, Third (surgery)
  • Osteotomy
  • Pain Measurement
  • Pain, Postoperative (drug therapy)
  • Piroxicam (administration & dosage)
  • Tooth, Impacted (surgery)
  • Treatment Outcome
  • Trismus (drug therapy, etiology)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: